M. Paul Murphy, PhD, professor of molecular and cellular biochemistry and researcher at the UK Sanders-Brown Center on Aging, has been appointed chair of the Chronic Dysfunction and Integrative Neurodegeneration (CDIN) study section for the National Institutes of Health (NIH).
“CDIN is one of the important federal advisory panels (study sections) that evaluate the scientific and technical merit of applications for NIH funding,” said Dr. Murphy.
NIH study sections play a critical role in advancing biomedical research by reviewing grant applications as a part of the process that determines which proposals will receive funding. CDIN evaluates pre-clinical and basic science research aimed at developing new therapies and approaches for Alzheimer’s disease and other age-related neurological disorders.
As chair, Dr. Murphy will lead discussions and guide the review process to ensure that all applicants receive a fair and thorough evaluation. “Being appointed chair of CDIN is a great honor, and I hope I will be able to carry on capably in the footsteps of those who have served before,” said Dr. Murphy.
Dr. Murphy’s research focuses on understanding the earliest changes in the brain that lead to Alzheimer’s disease to identify strategies for prevention and treatment. This national recognition reflects his scientific leadership and ongoing contributions to the study of neurodegeneration.
Peter T. Nelson, MD, PhD, professor of pathology and laboratory medicine and director of neuropathology at Sanders-Brown, has previously served as a member of the CDIN study section.